Lincoln, MA, United States of America

Jeno Gyuris

This inventor holds 29 USPTO granted patents and 14 published patent applications, plus 4 CIPO patents and 8 EPO patents, primarily in Cardiac and Renal Treatments. Top assignees: Aveo Pharmaceuticals, Inc., Xoma Technology Ltd., Xoma Technologies, Ltd.. Active years: 2010-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jeno Gyuris. Retrieved from https://idiyas.com/inventor/jeno-gyuris

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 29 

% Patents Active = 75.9

 

 

Average Co-Inventor Count = 8.6

ph-index = 7

Forward Citations = 147(Granted Patents)


Location History:

  • Winchester, MA (US) (2010)
  • Lincoln, MA (US) (2011 - 2024)

Company Filing History:


Years Active: 2010-2026

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
GDF15 Modulator
Anti-ErbB3 Antibodies
Chronic Kidney Disease
Congestive Heart Failure
Anti-FGFR2 Antibodies
Hepatocyte Growth Factor
Anti-Notch3 Antibodies
Tumor Response Prediction
Binding Proteins
Anti-RON Antibodies
Fibroblast Growth Factor Receptor
Renal Dysfunction
29 patents (USPTO):Explore Patents

Title: **Jeno Gyuris: Innovator in Renal Treatments**

Introduction

Jeno Gyuris is a notable inventor based in Lincoln, MA, with an impressive portfolio of 26 patents. His contributions to the field of medical science, particularly in the treatment of chronic kidney disease and related renal dysfunctions, have the potential to significantly improve patient outcomes and quality of life.

Latest Patents

Among Jeno Gyuris's latest patents is a groundbreaking invention titled "Treatment of chronic kidney disease and other renal dysfunction using a GDF15 modulator." This invention outlines methods and compositions to treat various renal-related disorders, including chronic kidney disease, end-stage renal failure, and diabetes. The approach focuses on developing compositions that reduce or inhibit GDF15 activity, which plays a critical role in kidney health. Another innovative patent features "Anti-GDF-15 antibodies," which are monoclonal antibodies designed to bind and inhibit the activity of human GDF15. This treatment is particularly beneficial for addressing body weight loss, including cachexia, associated with the over-expression of GDF15.

Career Highlights

Jeno Gyuris has made significant strides in the pharmaceutical industry through his collaborations with companies such as Aveo Pharmaceuticals and Xoma Technology Ltd. His expertise in renal treatments has positioned him as a leading figure in developing valuable therapeutic solutions.

Collaborations

Throughout his career, Jeno has worked alongside esteemed colleagues like William M Winston, Jr. and Lyne Breault. These collaborations have facilitated the exchange of innovative ideas and contribute to the advancement of healthcare solutions, specifically in renal therapy.

Conclusion

Jeno Gyuris's contributions to the field of renal treatment through his inventions and patents highlight his dedication to improving medical technology. With a strong focus on chronic kidney disease and related disorders, he continues to inspire innovation that may lead to better health outcomes for countless patients. His work exemplifies the vital role of inventors in enhancing healthcare through groundbreaking inventions.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…